MCID: DRG024
MIFTS: 41

Drug Allergy

Categories: Immune diseases

Aliases & Classifications for Drug Allergy

MalaCards integrated aliases for Drug Allergy:

Name: Drug Allergy 12 15 17
Allergy Drug 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0060500

Summaries for Drug Allergy

Disease Ontology : 12 A hypersensitivity reaction type I disease triggered by a drug.

MalaCards based summary : Drug Allergy, also known as allergy drug, is related to allergic hypersensitivity disease and asthma. An important gene associated with Drug Allergy is IL4R (Interleukin 4 Receptor), and among its related pathways/superpathways are Allograft rejection and IL4-mediated signaling events. The drugs Tranexamic Acid and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and breast, and related phenotype is digestive/alimentary.

Wikipedia : 77 A drug allergy is an allergy to a drug, most commonly a medication, and is a form of adverse drug... more...

Related Diseases for Drug Allergy

Diseases related to Drug Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 allergic hypersensitivity disease 30.4 MS4A2 IL5 IL4R
2 asthma 29.8 MS4A2 IL5 IL4R CYP3A4
3 ige responsiveness, atopic 29.7 MS4A2 IL5 IL4R
4 food allergy 29.6 MS4A2 IL5 ALB
5 beta-lactam allergy 11.4
6 aspirin allergy 11.0
7 carbamazepine allergy 11.0
8 abacavir allergy 11.0
9 isoniazide allergy 11.0
10 lidocaine allergy 11.0
11 mepivacaine allergy 11.0
12 phenobarbital allergy 11.0
13 phenytoin allergy 11.0
14 ranitidine allergy 11.0
15 corticosteroid allergy 11.0
16 sulfonamide allergy 11.0
17 sulfamethoxazole allergy 11.0
18 suprofen allergy 11.0
19 thiopental allergy 11.0
20 d-mannitol allergy 11.0
21 cephalosporin allergy 11.0
22 amodiaquine allergy 11.0
23 chlorhexidine allergy 11.0
24 cyclophosphamide allergy 11.0
25 succinylcholine allergy 11.0
26 trimethoprim allergy 11.0
27 diclofenac allergy 11.0
28 carbapenem allergy 11.0
29 rocuronium allergy 11.0
30 sulfasalazine allergy 11.0
31 tubocurarine allergy 11.0
32 quinidine allergy 11.0
33 melphalan allergy 11.0
34 co-trimoxazole allergy 11.0
35 sodium aurothiomalate allergy 11.0
36 disodium cromoglycate allergy 11.0
37 phthalyl group allergy 11.0
38 alcuronium bromide allergy 11.0
39 gallamine allergy 11.0
40 patent blue v allergy 11.0
41 oxirane allergy 11.0
42 sinusitis 10.3 IL5 IL4R
43 pollen allergy 10.2 IL5 IL4R
44 esophageal candidiasis 10.2 CYP3A4 ATP12A
45 duodenitis 10.2 INS ATP12A
46 neurodermatitis 10.2 MS4A2 INS
47 esophagitis, eosinophilic, 1 10.2 IL5 ATP12A
48 eosinophilic gastritis 10.2 IL5 ATP12A
49 functional gastric disease 10.1 INS ATP12A
50 severe nonproliferative diabetic retinopathy 10.1 INS ALB

Graphical network of the top 20 diseases related to Drug Allergy:



Diseases related to Drug Allergy

Symptoms & Phenotypes for Drug Allergy

MGI Mouse Phenotypes related to Drug Allergy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.02 ALB ATP12A IL4R IL5 INS

Drugs & Therapeutics for Drug Allergy

Drugs for Drug Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tranexamic Acid Approved Phase 4 1197-18-8 5526
2
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
3
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
4
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6 774
5
Epinastine Approved, Investigational Phase 4 80012-43-7 3241
6
Omalizumab Approved, Investigational Phase 4,Phase 1 242138-07-4
7
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
8
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
13
Methotrexate Approved Phase 4,Phase 3,Not Applicable 1959-05-2, 59-05-2 126941
14
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
15
Metronidazole Approved Phase 4 443-48-1 4173
16
Clarithromycin Approved Phase 4 81103-11-9 84029
17
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
18
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
19
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
20
Sodium Citrate Approved, Investigational Phase 4,Phase 1 68-04-2
21
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
22
Sulfamethoxazole Approved Phase 4,Phase 3,Not Applicable 723-46-6 5329
23
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Not Applicable 738-70-5 5578
24
leucovorin Approved Phase 4,Phase 3,Not Applicable 58-05-9 6006 143
25
Dapsone Approved, Investigational Phase 4 80-08-0 2955
26
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
27
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
28
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
29
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
31
Calcium Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 7440-70-2 271
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59-30-3 6037
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 77-92-9 311
35
BCG vaccine Investigational Phase 4
36 Antifibrinolytic Agents Phase 4
37 Coagulants Phase 4
38 Hemostatics Phase 4
39 Diphosphonates Phase 4
40 Calcium, Dietary Phase 4,Phase 3,Not Applicable
41 Calciferol Phase 4
42 Bone Density Conservation Agents Phase 4
43 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
48 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Not Applicable
49 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Ophthalmic Solutions Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section Unknown status NCT02279186 Phase 4 Tranexamic Acid
2 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
3 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
4 Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment Completed NCT02982603 Phase 4 Qinggongshoutao Bolus;Ginkgo Biloba Extract 761;Placebos
5 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
6 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Recruiting NCT01966640 Phase 4
7 Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) Completed NCT00367016 Phase 4 Xolair (Omalizumab);Placebo
8 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4 205.5 mcg of azelastine hydrochloride;137 mcg of azelastine hydrochloride
9 Grass Pollen Subcutaneous Immunotherapy in Elderly Patients Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
10 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. Completed NCT01694108 Phase 4
11 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
12 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
13 Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori Completed NCT03087162 Phase 4 Dexlansoprazole 60 mg once daily
14 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
15 Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy Recruiting NCT03708848 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole;Levofloxacin;Tetracycline
16 Co-trimoxazole as Maintenance Therapy for Meliodosis Active, not recruiting NCT01420341 Phase 4 Co-trimoxazole 12;Co-trimoxazole 20
17 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
18 Effect of Dexmedetomidine on Emergence Agitation in Children With or Without Tube Insertion Under General Anesthesia Completed NCT01535287 Phase 4 Dexmedetomidine
19 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
20 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
21 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
22 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
23 Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer Unknown status NCT02794493 Phase 3 Traditional Chinese Medicine Formula LC09
24 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
25 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
26 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
27 Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin) Terminated NCT00505648 Phase 3 Tegeline®
28 Phase III Cat-PAD Follow-on Study Completed NCT02040844 Phase 3 Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
29 Efficacy and Safety of Grass-SPIRE Registration Study Withdrawn NCT02795273 Phase 2, Phase 3 Grass-SPIRE;Placebo
30 Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery Completed NCT01294163 Phase 3 Xenon;Sevoflurane;Propofol
31 A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy Completed NCT00053638 Phase 3 efavirenz;tenofovir;abacavir/lamivudine
32 A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis Completed NCT01018862 Phase 3 Azelastine hydrochloride nasal spray 0.15%;Azelastine hydrochloride nasal spray 0.10%;Placebo
33 ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia Completed NCT00396526 Phase 3 Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.
34 Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze Completed NCT00407394 Phase 3 Amoxycillin
35 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies Completed NCT00712920 Phase 3 0.15% azelastine hydrochloride;0.1% azelastine hydrochloride;Placebo
36 A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies Completed NCT00720278 Phase 3 0.15% azelastine hydrochloride 1644 mcg daily;0.1% azelastine hydrochloride 1096 mcg daily;Placebo
37 SUBLIVAC FIX Birch Phase III Short-term Efficacy Completed NCT02231307 Phase 3 SUBLIVAC FIX Birch
38 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00824473 Phase 3 Placebo;0.15% azelastine hydrochloride
39 A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00719862 Phase 3 Placebo nasal spray;0.15% azelastine hydrochloride Nasal Spray
40 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00660829 Phase 3 Placebo;0.15% Azelastine Hydrochloride
41 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00660517 Phase 3 MP29-02;azelastine Hcl;fluticasone propionate;placebo
42 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00651118 Phase 3 Placebo;azelastine Hcl;azelastineHcl / fluticasone propionate;fluticasone propionate
43 A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00740792 Phase 3 azelastine HCl/fluticasone propionate;azelastine Hcl;fluticasone propionate;placebo
44 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00883168 Phase 3 Placebo;azelastineHcl;fluticasone propionate;azelastine Hcl/fluticasone propionate
45 Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis Completed NCT01731249 Phase 3
46 Avanz Phleum Pratense Maintenance Dose Completed NCT01438827 Phase 2, Phase 3 Avanz Phleum pratense;Placebo
47 Improving Safety by Basic Computerizing Outpatient Prescribing Completed NCT01091038 Phase 2, Phase 3
48 Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers Completed NCT00569777 Phase 3
49 Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers Completed NCT00889252 Phase 3
50 Natalizumab Re-Initiation of Dosing Completed NCT00306592 Phase 3

Search NIH Clinical Center for Drug Allergy

Genetic Tests for Drug Allergy

Anatomical Context for Drug Allergy

MalaCards organs/tissues related to Drug Allergy:

42
Testes, Skin, Breast, Eye, T Cells, Salivary Gland, Liver

Publications for Drug Allergy

Articles related to Drug Allergy:

(show top 50) (show all 473)
# Title Authors Year
1
A EAACI drug allergy interest group survey on how European allergy specialists deal with β-lactam allergy. ( 30637768 )
2019
2
Drug allergy in children and adults: Is it the double X chromosome? ( 30465863 )
2019
3
Controversies in drug allergy: Consensus documents from the world experts. ( 30612666 )
2019
4
Uncovering new potential culprits in drug allergy: non-vitamin K oral anticoagulants. ( 30638357 )
2019
5
Improving drug allergy management in Australia: education, communication and accurate information. ( 30712299 )
2019
6
BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily Practice? ( 30859323 )
2019
7
Nanoallergen Platform for the Detection of Platin Drugs Allergies. ( 30682456 )
2019
8
Risk factors for drug allergies in Chinese children. ( 30903997 )
2019
9
Asthma, Family History of Drug Allergy, and Age Predict Amoxicillin Allergy in Children. ( 29226807 )
2018
10
Hematemesis Due to Drug Allergy to Oral Prednisolone in a Patient with Ulcerative Colitis. ( 30568137 )
2018
11
Drug allergy evaluation for betalactam hypersensitivity: Cross-reactivity with cephalosporines, carbapenems and negative predictive value. ( 28577519 )
2018
12
A survey of drug allergy training opportunities in the United States. ( 28958742 )
2018
13
What can we learn in drug allergy management from World Health Organization's international classifications? ( 29105793 )
2018
14
Fifteen-minute consultation: A child with a suspected drug allergy. ( 29122832 )
2018
15
Evaluation of 'Definite' Anaphylaxis Drug Allergy Alert Overrides in Inpatient and Outpatient Settings. ( 29124665 )
2018
16
The Role of the Clinical History in Drug Allergy Prediction. ( 29310757 )
2018
17
Multiple drug intolerance syndrome and multiple drug allergy syndrome: Epidemiology and associations with anxiety and depression. ( 29574787 )
2018
18
Identification and management of drug allergy. ( 29583170 )
2018
19
Dendrimeric Antigens for Drug Allergy Diagnosis: A New Approach for Basophil Activation Tests. ( 29695102 )
2018
20
Diagnosing and managing drug allergy. ( 29712672 )
2018
21
Sulfonamide Drug Allergy. ( 29876667 )
2018
22
Clarification of Drug Allergy Information Using a Standardized Drug Allergy Questionnaire and Interview. ( 30100688 )
2018
23
Improving drug allergy management in Australia: education, communication and accurate information. ( 30157407 )
2018
24
Clinical Decision Support Systems for Drug Allergy Checking: Systematic Review. ( 30194058 )
2018
25
TEMPORARY REMOVAL: Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing. ( 30245291 )
2018
26
Drug allergy. ( 30275849 )
2018
27
Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017). ( 30276869 )
2018
28
Drug Allergy. ( 30308679 )
2018
29
Overview of Drug Allergy: From Immunogenetic Basis to Practice. ( 30387427 )
2018
30
New role for the modern allergist in drug allergy: Assess, diagnose, and de-label. ( 30389081 )
2018
31
Controversies in drug allergy: Testing for delayed reactions. ( 30573342 )
2018
32
Controversies in drug allergy: In vitro testing. ( 30573343 )
2018
33
Controversies in Drug Allergy: Consensus Documents From the World Experts. ( 30573420 )
2018
34
Controversies in Drug Allergy: Radiographic Contrast Media. ( 30573421 )
2018
35
Controversies in Drug Allergy: Drug Allergy Pathways. ( 30573422 )
2018
36
Controversies in drug allergy: consensus documents from the world experts. ( 30598722 )
2018
37
Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium. ( 30598723 )
2018
38
A cross-sectional observational study of high override rates of drug allergy alerts in inpatient and outpatient settings, and opportunities for improvement. ( 26993641 )
2017
39
Designing Predictive Models for Beta-Lactam Allergy Using the Drug Allergy and Hypersensitivity Database. ( 28739365 )
2017
40
Frequency and Risk Factors of Penicillin and Amoxicillin Allergy in Suspected Patients with Drug Allergy. ( 28112529 )
2017
41
Towards improved drug allergy alerts: Multidisciplinary expert recommendations. ( 27729200 )
2017
42
Cutaneous Manifestation of Drug Allergy and Hypersensitivity. ( 27886905 )
2017
43
Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. ( 28122115 )
2017
44
Anaphylaxis during general anaesthesia: experience from a drug allergy centre in the UK. ( 28164272 )
2017
45
The Importance of Prolonged Provocation in Drug Allergy - Results From a Danish Allergy Clinic. ( 28454683 )
2017
46
Drug Allergy: Phenotypes, Endotypes, and Biomarkers. ( 28483316 )
2017
47
Drug allergy/hypersensitivity in adults and children. ( 28598865 )
2017
48
Frequency of self-reported drug allergy: A systematic review and meta-analysis with meta-regression. ( 28779998 )
2017
49
Pattern of inpatient referrals to a drug allergy unit in Kuwait. ( 29249136 )
2017
50
Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. ( 29293931 )
2017

Variations for Drug Allergy

Expression for Drug Allergy

Search GEO for disease gene expression data for Drug Allergy.

Pathways for Drug Allergy

GO Terms for Drug Allergy

Molecular functions related to Drug Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 8.62 ALB CYP3A4

Sources for Drug Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....